StreetAlpha.app
Home › Stocks › ARDX

Ardelyx, Inc. (ARDX)

Healthcare
$2.99
▼ −2.29%
LAST CLOSE · NOV 20

Ardelyx sells IBSRELA and XPHOZAH, prescription medicines for irritable bowel syndrome and elevated phosphorus in dialysis patients. It last closed at $2.99 on Nov 20, down 2.29% on the day. The next earnings report for ARDX is expected around Thu, Feb 18, 2027, after the close. For the quarter ended Sep 2026, ARDX reported EPS of $0.00 on revenue of $127.7M, with revenue up 15.7% from a year ago. Over its last 8 reports the stock moved an average of 16.6% the session after earnings. Over the last 12 months ARDX insiders bought $1.9M of stock on the open market and sold $4.3M, according to SEC Form 4 filings.

AI Auto Pilots
Is ARDX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ARDX.

Key Stats

Last 12 months
Results
Revenue
$468.2M
+17.6% vs a year ago
Net income
−$55.5M
−11.8% margin
EPS (diluted)
−$0.23
Free cash flow
−$16.0M
−3.4% margin
Valuation
Market cap
$751.6M
251.4M shares
P/E
–
No P/E while losing money
Price to sales
1.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$46.3M
At Sep 30
Debt
$252.4M
At Sep 30
Shareholder equity
$164.0M
Shares outstanding
251.4M
At Oct 27
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $10.1M$10.1MFY2021FY2022: $52.2M$52.2MFY2022FY2023: $124.5M$124.5MFY2023FY2024: $333.6M$333.6MFY2024FY2025: $407.3M$407.3MFY2025

From ARDX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
Feb 18
Estimated date · After the close
Reported EPS
$0.00
Quarter ended Sep 2026
Year ago EPS
$0.00
Same quarter last year
Revenue
$127.7M
+15.7% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.02Dec '24Mar 2025: -$0.17Mar '25Jun 2025: -$0.08Jun '25Sep 2025: $0.00Sep '25Dec 2025: -$0.01Dec '25Mar 2026: -$0.15Mar '26Jun 2026: -$0.07Jun '26Sep 2026: $0.00Sep '26Latest $0.00
Revenue by quarter
Dec 2024: $116.1MDec '24Mar 2025: $74.1MMar '25Jun 2025: $97.7MJun '25Sep 2025: $110.3MSep '25Dec 2025: $125.2MDec '25Mar 2026: $94.5MMar '26Jun 2026: $120.9MJun '26Sep 2026: $127.7MSep '26Latest $127.7M
How ARDX moved after its last 8 reports
Average move the session after a report ±16.6%
Nov 3, 2026After the close+8.6%
Aug 6, 2026After the close−17.9%
Apr 30, 2026After the close+8.7%
Feb 19, 2026After the close−15.0%
Jan 8, 2026Time not announced+20.1%
Oct 30, 2025After the close+21.0%
Aug 4, 2025After the close+16.9%
May 1, 2025After the close−24.5%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ARDXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ARDX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ARDX

Technical Analysis

ARDX · as of the Nov 20 close · updated each morning
Downtrend

The stock is 2% below its 20 day and 8% below its 50 day average. It is 67% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 43). The nearest support is the swing low (Oct 28) at $2.96, and the nearest resistance the Pivot at $3.01.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 5.1%/day
Key levels
$8.4052 week high+180.9%
$4.99200 day average+66.9%
$3.85100 day average+28.8%
$3.2250 day average+7.7%
$3.16Swing high (Oct 29)+5.7%
$3.0620 day average+2.3%
$3.06Pivot R1+2.3%
$3.01Pivot+0.7%
$2.99Last close
$2.96Swing low (Oct 28)−1.0%
$2.93Pivot S1−2.0%
$2.8052 week low−6.4%
Indicators
RSI (14)43.07Middle of its rangeNeutral
MACD-0.05Above its signal lineBullish
Stochastic42.1Middle of its rangeNeutral
ADX (14)16.4No clear trend
Williams %R-68.8Oversold below −80, overbought above −20Neutral
CCI (20)-61.1Oversold below −100, overbought above 100Neutral
Rate of change+3.8%Change over 10 sessionsBullish
ATR (14)$0.15Typical daily range, 5.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ARDX

What happened before

See how ARDX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ARDX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ARDX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ARDXHow many large options trades hit ARDX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

ARDX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼100 buying vs 141 selling
  • ▲Held by funds +2.4 pts
  • ▼Funds holding -24
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding226250−9.6%
In funds' top 1000–
Held by funds73.0%70.6%+2.4 pts
New / increased31 / 6941 / 87−21.9%
Reduced / sold out86 / 5587 / 34+16.5%
Put/call ratio18.490.39+4695.8%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ARDX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ARDX Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$1.9M1 buy · 1 insider
Sold$4.3M38 sales · 9 insiders
54% of the selling was under pre-arranged trading plans.
2026-01 sold $349K2026-02 bought $1.9M2026-02 sold $769K2026-03 sold $243K2026-04 sold $262K2026-05 sold $803K2026-06 sold $727K2026-07 sold $211K2026-08 sold $486KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Aug 21John E BishopSee RemarksSale19,750$3.86$76K
Aug 21Michael RaabPresident & CEOSale58,574$3.86$226K
Aug 21Laura A WilliamsChief Patient OfficerSale10,739$3.86$41K
Aug 21Mike KelliherChief Business OfficerSale7,758$3.86$30K
Aug 21Eric Duane FosterChief Commercial OfficerSale8,562$3.86$33K
Aug 21Joseph James ReillySee RemarksSale3,982$3.86$15K
Every insider buy and sale for ARDX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ARDX insider trades →

From SEC Form 4 filings by ARDX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARDX is in one of them and how their past ARDX trades turned out.

ARDX in the AI portfolios
Loading…

ARDX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ARDX in an article yet. Here's the latest on the wider market.

ARDX in the news

About Ardelyx

Ardelyx is a biopharmaceutical company based in Fremont, California. It sells two prescription medicines, both made from the active ingredient tenapanor. IBSRELA treats adults with irritable bowel syndrome with constipation, and XPHOZAH lowers phosphorus levels in adults with chronic kidney disease who are on dialysis. The company sells these medicines in the United States and is also studying tenapanor for chronic idiopathic constipation.

Headquarters
Fremont, CA
Founded
2007